PreserVision is the #1 doctor recommended brand of eye vitamins for people with moderate to advanced Age-related Macular Degeneration (AMD). *1,2 PreserVision AREDS and AREDS 2 formulas are patented and based on the clinical evidence from the landmark, independent Age-Related Eye Disease Studies also known as AREDS and AREDS2. PreserVision formulas cannot be found in any store brand vitamins.
Ask your eye care professional if PreserVision Eye Vitamins are right for you. Visit PreserVision.com to learn more:
PreserVision AREDS 2 Formula builds on the original, clinically proven PreserVision AREDS formula, with lutein and zeaxanthin replacing beta-carotene. This advanced formula is based on evidence from the National Eye Institute’s Age-Related Eye Disease Study 2 (AREDS2).
The PreserVision AREDS 2 Formula is also available in a convenient, great-tasting, mixed berry chewable.
This convenient 2-in-1 formula combines the benefits of PreserVision AREDS 2 Formula plus essential vitamins and nutrients found in daily multivitamins* making it simpler to take your supplements by reducing the number of pills taken each day.
This 2 per day soft gel format is based on the original Bausch + Lomb PreserVision Eye Vitamin AREDS Formula (Tablets), tested and proven effective in the National Eye Institute's Age-Related Eye Disease Study (AREDS)*.
Convenient to take, 2 per day soft gel format, AREDS-based formula that replaces beta-carotene with lutein. For those who should avoid beta-carotene, such as current or former smokers.
The original Bausch + Lomb PreserVision Eye Vitamin AREDS Formula was the actual supplement tested and proven effective in the National Eye Institute's Age-Related Eye Disease Study (AREDS)*. 4 tablets per day format.
| *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. |
AREDS and AREDS2 are registered trademarks of the United States Department of Health and Human Services (HHS).
1. IRI Syndicated Data, 2018
2. IQVIA December 31, 2018
PVN.0036.USA.19